Yao Jiang

Yao Jiang

Auto-generated profile, based on publicly available information

Yao Jiang

Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2013 in Leukemia & Lymphoma
Verified
Journal Article
Open access
PDF file
AWAlison R. Walker
Alison R. Walker
RKRebecca Klisovic
Rebecca Klisovic
JJJeffrey S. Johnston
Jeffrey S. Johnston
YJYao Jiang
Yao Jiang
SGSusan Geyer
Susan Geyer
WBWilliam Blum
William Blum
This phase I study was conducted to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the heat shock protein 90 (HSP90) inhibitor 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib, and to provide pharmacokinetic data in relapsed or refractory acute myeloid leukemia (AML). Eleven patients were enrolled. The MTD was 17-AAG 150 mg/m2 and bortezomib 0.7 mg/m2. Hepatic toxicity and cardiac toxicity were dose limiting. Co-administration on day 4 led to a decrease in clearance (p = 0.005) and increase in AUC (p = 0.032) of 17-amino-17-demethoxygeldanamycin (17-AG), not observed when 17-AAG was administered alone. Pharmacokinetic parameters of patients who developed toxicities and those who did not were not different. The combination of 17-AAG and bortezomib led to toxicity without measurable response in patients with relapsed or refractory AML. Pharmacokinetic data provide insight for studies of related agents in AML. Next-generation HSP90 inhibitors are appealing for further development in this area.

30 December 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YJYao Jiang
Yao Jiang
JHJimin He
Jimin He
YGYongcan Guo
Yongcan Guo
HTHualin Tao
Hualin Tao
FPFei Pu
Fei Pu
YLYiqin Li
Yiqin Li

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YJYao Jiang
Yao Jiang
ZHZuohong Hu
Zuohong Hu
ZZZhihua Zuo
Zhihua Zuo
YLYiqin Li
Yiqin Li
FPFei Pu
Fei Pu
HTHualin Tao
Hualin Tao
Background. Cervical cancer (CC) is one of the most common female malignant tumors. And cervical intraepithelial neoplasia (CIN) is the precancerous lesion of CC, which can progress to invasive CC. MicroRNAs (miRNAs) have been found to be potential diagnostic biomarkers for CIN or CC. However, recently, the lack of sufficient studies about the diagnostic value of miRNAs for CIN made it challenging to separately investigate the diagnostic efficacy of miRNAs for CIN. Likewise, the conclusions among those studies were discordant. Therefore, we conducted this meta‐analysis, aimed at evaluating the diagnostic efficacy of miRNAs for CIN and CC patients. Methods. Literature search was performed in PubMed, Embase, and Web of Science databases. Pooled sensitivity, specificity, and other diagnostic parameters were calculated through Stata 14.0 software. Furthermore, subgroup analyses and metaregression analysis were conducted to explore the main sources of heterogeneity. Results. Ten articles covering 50 studies were eligible, which included 5,908 patients and 4,819 healthy individuals. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were 0.81 (95% CI, 0.77‐0.85), 0.86 (95% CI, 0.83‐0.89), 5.9 (95% CI, 4.5‐7.7), 0.22 (95% CI, 0.17‐0.28), 27 (95% CI, 17‐44), and 0.91 (95% CI, 0.88‐0.93), respectively. Additionally, the ethnicity and internal reference were the main sources of heterogeneity. Conclusions. Circulating miRNAs can be a promising noninvasive diagnostic biomarker for CIN and early CC, especially miR‐9 and miR‐205, which need to be verified by large‐scale studies.

14 April 2025 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
YJYao Jiang
Yao Jiang
LMLing Meng
Ling Meng
ZLZhenhua Liu
Zhenhua Liu
QWQian Wu
Qian Wu
YDYingqiang Dang
Yingqiang Dang
CYChongge You
Chongge You
This study investigates the relationships between folate intake, RBC folate, serum folate levels, and stroke risk, with an emphasis on the mediating roles of the dietary inflammatory index (DII) and systemic immune-inflammation index (SII). A cross-sectional analysis was conducted using 24,106 participants from NHANES (2007-2018). Associations were assessed with weighted multivariate logistic regression, adjusting for key confounders. Propensity score matching (PSM) was applied, yielding 1,838 matched participants, respectively. Nonlinear relationships were analyzed with restricted cubic splines, and mediation analysis was performed for DII and SII. Post-PSM, folate intake in Q2 (252-350 μg/day), Q3 (350-484 μg/day), and Q4 (> 484 μg/day) was significantly inversely associated with stroke risk (trend P < 0.05), with adjusted ORs of 0.62 (95 % CI: 0.45-0.85), 0.65 (95 % CI: 0.46-0.90), and 0.60 (95 % CI: 0.42-0.86), respectively. Serum folate levels in Q3 (37.0 - 54.8 nmol/L) were also protective (OR: 0.47, 95 % CI: 0.32-0.68, trend P < 0.05). Serum folate levels exhibited a biphasic effect, with the lowest stroke risk at 41.9 nmol/L before PSM and 43.3 nmol/L after PSM. Mediation analysis showed DII mediated 45.2 % of the relationship between folate intake and stroke risk (P = 0.018), while SII's mediation effect was minimal (0.412 %, P = 0.016). No significant interactions were observed between folate intake, serum folate and stratified variables (P > 0.05) after PSM. Higher folate intake lowers stroke risk, with DII playing a significant mediating role, while serum folate presents a biphasic risk pattern. Personalized dietary strategies addressing folate intake and inflammation may be crucial for stroke prevention.

1 December 2019 in Gene
Verified
Journal Article
Closed access
JYJuan Yao
Juan Yao
YCYu Cheng
Yu Cheng
DZDan Zhang
Dan Zhang
JFJia Fan
Jia Fan
ZZZijun Zhao
Zijun Zhao
YGYongcan Guo
Yongcan Guo

1 October 2020 in Pathology - Research and Practice
Verified
Journal Article
Closed access
ZZZhihua Zuo
Zhihua Zuo
YJYao Jiang
Yao Jiang
SZShanshui Zeng
Shanshui Zeng
YLYiqin Li
Yiqin Li
JFJia Fan
Jia Fan
HTHualin Tao
Hualin Tao